bioAffinity Technologies, Inc. (NASDAQ: BIAF)

BioAffinity Technologies, Inc. specializes in the development and commercialization of innovative diagnostic and therapeutic technologies, primarily focusing on early detection and treatment of lung cancer and other respiratory diseases. The company leverages advanced flow cytometry techniques to create proprietary diagnostic tests and therapeutic platforms, aiming to improve patient outcomes through early intervention and targeted treatments. BioAffinity operates within the biotechnology sector, combining cutting-edge scientific research with clinical applications to address critical healthcare needs.

The company generates revenue through the sale of its diagnostic products, particularly its flagship test, CyPath® Lung, which is designed for the early detection of lung cancer. CyPath® Lung utilizes a non-invasive sputum sample collection method, making it patient-friendly and cost-effective. The test is marketed to clinical laboratories, healthcare providers, and patients, offering a balanced approach to lung cancer diagnosis by providing high specificity and sensitivity. Additionally, BioAffinity is exploring the development of precision diagnostics for asthma and Chronic Obstructive Pulmonary Disease (COPD), targeting specific therapeutic markers to identify patients who can benefit from emerging treatments. The company also conducts research on therapeutic platforms, including siRNA and porphyrin conjugates, aimed at treating various types of cancer.

• Diagnostic Segment: BioAffinity's diagnostic segment is centered around CyPath® Lung, a proprietary test that uses flow cytometry to analyze sputum samples for early lung cancer detection. The test is designed to be noninvasive, cost-effective, and highly accurate, catering to clinical laboratories and healthcare providers. The company also has a patent portfolio covering diagnostic applications, including compensation beads for flow cytometry, and is expanding its diagnostic capabilities to include COPD and asthma precision diagnostics.

• Therapeutic Segment: The therapeutic segment focuses on the development of innovative treatments for cancer, leveraging the company's research on siRNA and porphyrin conjugates. BioAffinity has identified specific cell membrane proteins, CD320 and LRP2, which play a crucial role in cancer cell uptake of TCPP, a synthetic porphyrin. The company is exploring the potential of these discoveries for therapeutic applications, aiming to selectively target and kill cancer cells while minimizing effects on normal cells.

BioAffinity Technologies holds a competitive position in the biotechnology industry, particularly in the diagnostic sector, where CyPath® Lung stands out for its noninvasive nature, high accuracy, and cost-effectiveness. The company's proprietary technology and strong intellectual property portfolio, including 17 issued patents and multiple pending applications, provide a robust foundation for its competitive advantages. BioAffinity's diagnostic tests are positioned to complement existing screening methods, offering a balanced approach that helps physicians make informed decisions about patient care. The company's research and development efforts in therapeutic platforms also position it as a potential leader in targeted cancer treatments, with strategic partnerships likely to play a key role in advancing these discoveries.

The company's customer base primarily consists of clinical laboratories, healthcare providers, and patients seeking early and accurate lung cancer detection. BioAffinity's diagnostic products are designed to meet the needs of these customers by providing reliable, noninvasive testing options that can improve patient outcomes and reduce healthcare costs. As the company expands its diagnostic and therapeutic offerings, it aims to serve a broader range of customers, including those in the asthma and COPD markets, and strategic partners interested in its therapeutic platforms.